je.st
news
Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off
2015-01-14 09:33:23| Biotech - Topix.net
New peer-reviewed scientific data from Rexahn is testimony to sound evidence of tumor shrinkage versus popular but problematic Gemzar. Risks include early data that may not translate in larger study results, possible funding needs, regulatory hurdles, and competition for more well-capitalized players.
Tags: off
face
lead
drug
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||